Nov 5 (Reuters) - Regeneron Pharmaceuticals Inc reported a 9% jump in third-quarter sales of its eye drug Eylea on Thursday, as easing restrictions boosted demand for non-COVID-19 treatments.
Regeneron, whose experimental COVID-19 antibody treatment President Donald Trump received during his illness, had struggled as the pandemic cut visits to the doctor’s office and dented demand for some non-COVID-19 drugs.
Eylea sales rose to $2.10 billion, from $1.92 billion a year ago.
Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles.